A vs. ZTS: Agilent vs. Zoetis Stock Comparison
How do Agilent (A) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Agilent (A) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while ZTS is classified in Pharmaceuticals.
| Profile Item | A | ZTS |
|---|---|---|
| Name | AgileThought, Inc. Class A Common Stock | Zoetis Inc. Class A Common Stock |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 49.28 billion USD | 32.26 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | November 18, 1999 | February 1, 2013 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | A | ZTS |
|---|---|---|
| Total Return (1Y) | 22.92% | -30.10% |
| Total Return (3Y, Annualized) | 19.33% | -20.42% |
| Total Return (5Y, Annualized) | 3.03% | -16.87% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | A | ZTS |
|---|---|---|
| Volatility (1Y, Annualized) | 33.10% | 38.23% |
| Beta (5Y) | 1.22 | 0.66 |
| Max Drawdown (5Y) | -38.09% | -70.45% |
| Avg. Volume (3M) | 2.25M | 4.65M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | A | ZTS |
|---|---|---|
| Sharpe Ratio (1Y) | 0.56 | -0.90 |
| Sortino Ratio (1Y) | 0.96 | -1.10 |
Profitability
ROE (TTM)
Both Agilent (A) at 20.97% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.97%
- Max
- 109.18%
- A
- 20.97%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
57.63%
- Max
- 109.18%
- ZTS
- 57.63%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Agilent (A) at 19.53% and Zoetis (ZTS) at 26.41% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.53%
- A
- 19.53%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.41%
- ZTS
- 26.41%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Agilent (A) at 25.56% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.56%
- Max
- 83.12%
- A
- 25.56%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.19%
- Max
- 83.12%
- ZTS
- 38.19%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | A | ZTS |
|---|---|---|
| ROE (TTM) | 20.97% | 57.63% |
| ROA (TTM) | 8.63% | 14.87% |
| Net Margin (TTM) | 19.53% | 26.41% |
| Operating Margin (TTM) | 25.56% | 38.19% |
| Gross Margin (TTM) | 53.65% | 71.65% |
Growth
Revenue Growth
Both Agilent (A) at 6.73% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Agilent (A) at 3.16% and Zoetis (ZTS) at 10.05% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | A | ZTS |
|---|---|---|
| Revenue Growth (YoY) | 6.73% | 2.28% |
| Revenue Growth (3Y CAGR) | 0.48% | 5.42% |
| EPS Growth (YoY) | 3.16% | 10.05% |
| EPS Growth (3Y CAGR) | 3.02% | 10.27% |
Financial Strength
Current Ratio (MRQ)
Both Agilent (A) at 2.05 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.05
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- A
- 2.05
- Min
- 0.10
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ZTS
- 2.35
- Min
- 0.10
Debt / Equity (MRQ)
Agilent (A) at 0.56 is near its industry mid-range for debt-to-equity ratio, while Zoetis (ZTS) at 2.80 sits above its benchmark range, pointing to a heavier debt load relative to equity.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.56
- Max
- 1.42
- Q3
- 0.65
- A
- 0.56
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.80
- ZTS
- 2.80
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | A | ZTS |
|---|---|---|
| Current Ratio (MRQ) | 2.05 | 2.35 |
| Debt / Equity (MRQ) | 0.56 | 2.80 |
| Net Debt / EBITDA | 1.15 | 1.92 |
Dividends
Dividend Yield (TTM)
Both Agilent (A) at 0.59% and Zoetis (ZTS) at 2.55% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.59%
- A
- 0.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.55%
- ZTS
- 2.55%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both Agilent (A) at 19.98% and Zoetis (ZTS) at 35.24% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.98%
- A
- 19.98%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.24%
- ZTS
- 35.24%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | A | ZTS |
|---|---|---|
| Dividend Yield (TTM) | 0.59% | 2.55% |
| Dividend Payout Ratio (TTM) | 19.98% | 35.24% |
Valuation
P/E Ratio (TTM)
Both Agilent (A) at 34.47 and Zoetis (ZTS) at 13.50 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.47
- Max
- 85.34
- Q3
- 43.46
- A
- 34.47
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.50
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- ZTS
- 13.50
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Agilent (A) at 6.68 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- A
- 6.68
- Q1
- 3.01
- Min
- 0.01
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.40
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ZTS
- 3.40
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both Agilent (A) at 6.69 and Zoetis (ZTS) at 9.80 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 13.53
- A
- 6.69
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.80
- Max
- 13.53
- ZTS
- 9.80
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | A | ZTS |
|---|---|---|
| P/E Ratio (TTM) | 34.47 | 13.50 |
| P/S Ratio (TTM) | 6.68 | 3.40 |
| P/B Ratio (MRQ) | 6.69 | 9.80 |
| Free Cash Flow Yield (TTM) | 2.15% | 6.36% |